TOBIN JAMES R 4
4 · TransMedics Group, Inc. · Filed May 22, 2026
Research Summary
AI-generated summary of this filing
TransMedics (TMDX) Director James R. Tobin Receives 2,922 RSU Award
What Happened James R. Tobin, a director of TransMedics Group, Inc. (TMDX), was granted 2,922 restricted stock units (RSUs) on May 20, 2026. The Form 4 reports an acquisition type "A" at $0.00 per unit (total reported acquisition value $0). Each RSU is a contingent right to receive one share of TransMedics common stock.
Key Details
- Transaction date: 2026-05-20; Form 4 filed 2026-05-22 (appears timely).
- Security: 2,922 RSUs granted, reported acquisition price $0.00; total reported value $0.
- Footnote: RSUs consist of contingent rights to receive one share each (vesting terms not specified in the filing).
- Shares owned after transaction: not specified in the supplied filing details.
- Transaction code: A = Award/Grant (not a market purchase or sale).
Context RSU grants are typically compensation awards and do not represent an immediate cash purchase or sale; they generally convert to shares only if and when vesting conditions are met. The $0 acquisition price on the Form 4 reflects grant accounting, not market value—market exposure occurs only upon vesting and delivery of shares.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-20+2,922→ 6,981 total
- 155,146(indirect: By Trust)
Common Stock
- 18,000(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.